Clinical Edge Journal Scan

Heavy drinking associated with increased risk for EOCRC irrespective of genetic risk


 

Key clinical point: Heavy alcohol use strongly contributes to increased early-onset colorectal cancer (EOCRC) risk irrespective of polygenic risk score (PRS) levels. Abstinence from heavy drinking may reduce EOCRC risk to a degree equivalent to having a much lower genetic risk.

Major finding: High (≥25 g/day) vs. low (0.1 to <25 g/day) lifetime average alcohol consumption was strongly associated with increased EOCRC risk (odds ratio 1.8; 95% CI 1.2-2.8). The effect of high lifetime alcohol consumption on EOCRC was equivalent to that of having 47 percentiles higher PRS (genetic risk equivalent 47; 95% CI 12-82).

Study details: This retrospective study included 5104 patients with colorectal cancer and 4131 non-colorectal cancer controls from the large, population-based German DACHS study.

Disclosures: The DACHS study was supported by the German Research Council and German Federal Ministry of Education and Research. The authors declared no conflicts of interest.

Source: Chen X et al. Alcohol consumption, polygenic risk score, and early- and late-onset colorectal cancer risk. EClinicalMedicine. 2022;49:101460 (May 20). Doi: 10.1016/j.eclinm.2022.101460

Recommended Reading

‘Great optimism’ greets immunotherapy responses in dMMR rectal cancer
MDedge Hematology and Oncology
Esophageal cancer screening isn’t for everyone: Study
MDedge Hematology and Oncology
At-home colorectal cancer testing and follow-up vary by ethnicity
MDedge Hematology and Oncology
AGA issues position statements on reducing CRC burden
MDedge Hematology and Oncology
AI-based CADe outperforms high-definition white light in colonoscopy
MDedge Hematology and Oncology
New treatment reduces risk of anal cancer in people with HIV
MDedge Hematology and Oncology
Intensified chemotherapy confers no additional benefits with panitumumab in RAS and BRAF wt mCRC
MDedge Hematology and Oncology
Atezolizumab added to FOLFOXIRI + bevacizumab seems safe and beneficial in previously untreated mCRC
MDedge Hematology and Oncology
Therapy trends in patients with mCRC after the second disease progression
MDedge Hematology and Oncology
Is iatrogenic tumor seeding a risk factor for metachronous CRC? Evidence suggests otherwise
MDedge Hematology and Oncology